This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.

The present invention provides high-complexity defined gut microbial communities capable of achieving substantial engraftment and having stability following human fecal community microbial challenge and methods of producing the same. Also provided are methods of using high-complexity defined gut microbial communities for the treatment of dysbiosis or a pathological condition in an animal.

The present invention provides high-complexity defined gut microbial communities capable of achieving substantial engraftment and having stability following human fecal community microbial challenge and methods of producing the same. Also provided are methods of using high-complexity defined gut microbial communities for the treatment of dysbiosis or a pathological condition in an animal.

Provided are a method for predicting a treatment response to cancer immunotherapy, the method comprising a step of evaluating, from feces isolated from a patient, the enrichment of a strain of the order TANB77 according to GTDB phylogenetic classification or taxa belonging to the order TANB77, and a step of predicting a treatment response of the patient to cancer immunotherapy on the basis of the enrichment of the order TANB77 or the taxa; a probiotics composition for improving a treatment response; a fecal microbiota transplantation composition; and a method for screening for candidate prebiotics by using same.

Compositions and methods for treating or preventing the progression of neurodegenerative diseases are provided herein. Exemplary compositions include bacterial compositions having an effective amount of viable, non-pathogenic microbes, viable, non-pathogenic bacteria, wherein at least one of the bacteria is a predatory bacteria such as Bdellovibrio bacteriovorus. The disclosed bacterial compositions can be used to treat or prevent the progression of neurodegenerative diseases such as ALS, Alzheimer's disease, Huntington's disease, and Parkinson's disease.

Compositions and methods for treating or preventing the progression of neurodegenerative diseases are provided herein. Exemplary compositions include bacterial compositions having an effective amount of viable, non-pathogenic microbes, viable, non-pathogenic bacteria, wherein at least one of the bacteria is a predatory bacteria such as Bdellovibrio bacteriovorus. The disclosed bacterial compositions can be used to treat or prevent the progression of neurodegenerative diseases such as ALS, Alzheimer's disease, Huntington's disease, and Parkinson's disease.

A composition of fecal material is prepared and administered to a subject suffering from alcohol craving, alcohol consumption and/or alcohol use disorder. The donor fecal material is enriched in beneficial microbiota associated with reduced alcohol craving and/or consumption and supplies beneficial microbiota in which the recipient is deficient, and reduces harmful microbes. Methods of preparing and administering are disclosed, along with the identification of beneficial and harmful microbiota families. The treatment is also useful for delivery of microbiota that are short chain fatty acid producers to reduce alcohol craving and/or consumption in subjects deficient in short chain fatty acids.

A composition of fecal material is prepared and administered to a subject suffering from alcohol craving, alcohol consumption and/or alcohol use disorder. The donor fecal material is enriched in beneficial microbiota associated with reduced alcohol craving and/or consumption and supplies beneficial microbiota in which the recipient is deficient, and reduces harmful microbes. Methods of preparing and administering are disclosed, along with the identification of beneficial and harmful microbiota families. The treatment is also useful for delivery of microbiota that are short chain fatty acid producers to reduce alcohol craving and/or consumption in subjects deficient in short chain fatty acids.

A sanitizing composition for restoring skin's natural balance of bacteria and/or increasing the production and/or activity of antimicrobial peptides is provided. The sanitizing composition includes about 0.005 wt. % to 15.0 wt. % of an active ingredient that is one or more of a probiotic, probiotic derivative, prebiotic, and a prebiotic derivative and at least one compound that delivers a sanitizing effect.

A sanitizing composition for restoring skin's natural balance of bacteria and/or increasing the production and/or activity of antimicrobial peptides is provided. The sanitizing composition includes about 0.005 wt. % to 15.0 wt. % of an active ingredient that is one or more of a probiotic, probiotic derivative, prebiotic, and a prebiotic derivative and at least one compound that delivers a sanitizing effect.